Ryan Zurakowski | University of Delaware (original) (raw)
Uploads
Papers by Ryan Zurakowski
Journal of clinical microbiology, 2012
Replicating genetically modified adenoviruses have shown promise as a new treatment approach agai... more Replicating genetically modified adenoviruses have shown promise as a new treatment approach against cancer. Recombinant adenoviruses replicate only in cancer cells which contain certain mutations, such as the loss of functional p53, as is the case in the virus ONYX-015. The successful entry of the viral particle into target cells is strongly dependent on the presence of the main receptor for adenovirus, the coxsackie- and adeno-virus receptor (CAR). This receptor is frequently down-regulated in highly malignant cells, rendering this population less vulnerable to viral attack. It has been shown that use of MEK inhibitors can up-regulate CAR expression, resulting in enhanced adenovirus entry into the cells. However, inhibition of MEK results in G1 cell cycle arrest, rendering infected cells temporarily unable to produce virus. This forces a tradeoff. While drug mediated up-regulation of CAR enhances virus entry into cancer cells, the consequent cell cycle arrest inhibits production of new virus particles and the replication of the virus. Optimal control-based schedules of MEK inhibitor application should increase the efficacy of this treatment, maximizing the overall tumor toxicity by exploiting the dynamics of CAR expression and viral production. We introduce two mathematical models of these dynamics and show simple optimal control based strategies which motivate this approach
Biomedical Engineering Online, 2011
Background Mathematical models of the immune response to the Human Immunodeficiency Virus demonst... more Background Mathematical models of the immune response to the Human Immunodeficiency Virus demonstrate the potential for dynamic schedules of Highly Active Anti-Retroviral Therapy to enhance Cytotoxic Lymphocyte-mediated control of HIV infection. Methods In previous work we have developed a model predictive control (MPC) based method for determining optimal treatment interruption schedules for this purpose. In this paper, we introduce a nonlinear observer for the HIV-immune response system and an integrated output-feedback MPC approach for implementing the treatment interruption scheduling algorithm using the easily available viral load measurements. We use Monte-Carlo approaches to test robustness of the algorithm. Results The nonlinear observer shows robust state tracking while preserving state positivity both for continuous and discrete measurements. The integrated output-feedback MPC algorithm stabilizes the desired steady-state. Monte-Carlo testing shows significant robustness to modeling error, with 90% success rates in stabilizing the desired steady-state with 15% variance from nominal on all model parameters. Conclusions The possibility of enhancing immune responsiveness to HIV through dynamic scheduling of treatment is exciting. Output-feedback Model Predictive Control is uniquely well-suited to solutions of these types of problems. The unique constraints of state positivity and very slow sampling are addressable by using a special-purpose nonlinear state estimator, as described in this paper. This shows the possibility of using output-feedback MPC-based algorithms for this purpose.
UMI, ProQuest ® Dissertations & Theses. The world's most comprehensive collection of dis... more UMI, ProQuest ® Dissertations & Theses. The world's most comprehensive collection of dissertations and theses. Learn more... ProQuest, Exploiting immune response dynamics in HIV therapy. by Zurakowski, Ryan Mark, Ph.D ...
… Control Conference, 2004. …, 2004
… Control Conference (ACC), …, 2010
… Control Conference (ACC), …, 2010
Journal of process …, 2011
American Control Conference, 2006, 2006
… Conference, 2004. 5th …, 2004
Journal of theoretical biology, 2007
… Control Conference, 2009. …, 2009
American Control Conference, 2008, 2008
Decision and Control, 2007 46th …, 2007
Proceedings of the American Control …, 2003
Journal of Theoretical Biology, 2006
Recently developed models of the interaction of the human immune system and the human immunodefic... more Recently developed models of the interaction of the human immune system and the human immunodeficiency virus (HIV) suggest the possibility of using interruptions of highly active anti-retroviral therapy (HAART) to simulate a therapeutic vaccine and induce cytotoxic lymphocyte (CTL) mediated control of HIV infection. We have developed a model predictive control (MPC) based method for determining optimal treatment interruption schedules for this purpose. This method provides a clinically implementable framework for calculating interruption schedules that are robust to errors due to measurement and patient variations. In this paper, we discuss the medical motivation for this work, introduce the MPC-based method, show simulation results, and discuss future work necessary to implement the method.
I. INTRODUCTION The development of resistance to a particular drug regimen necessitates a change ... more I. INTRODUCTION The development of resistance to a particular drug regimen necessitates a change in regimen, and there are, for every ap-plication, only a limited number of drug regimens available. If resistance develops to every available drug regimen, the patient will die. It is ...
Journal of clinical microbiology, 2012
Replicating genetically modified adenoviruses have shown promise as a new treatment approach agai... more Replicating genetically modified adenoviruses have shown promise as a new treatment approach against cancer. Recombinant adenoviruses replicate only in cancer cells which contain certain mutations, such as the loss of functional p53, as is the case in the virus ONYX-015. The successful entry of the viral particle into target cells is strongly dependent on the presence of the main receptor for adenovirus, the coxsackie- and adeno-virus receptor (CAR). This receptor is frequently down-regulated in highly malignant cells, rendering this population less vulnerable to viral attack. It has been shown that use of MEK inhibitors can up-regulate CAR expression, resulting in enhanced adenovirus entry into the cells. However, inhibition of MEK results in G1 cell cycle arrest, rendering infected cells temporarily unable to produce virus. This forces a tradeoff. While drug mediated up-regulation of CAR enhances virus entry into cancer cells, the consequent cell cycle arrest inhibits production of new virus particles and the replication of the virus. Optimal control-based schedules of MEK inhibitor application should increase the efficacy of this treatment, maximizing the overall tumor toxicity by exploiting the dynamics of CAR expression and viral production. We introduce two mathematical models of these dynamics and show simple optimal control based strategies which motivate this approach
Biomedical Engineering Online, 2011
Background Mathematical models of the immune response to the Human Immunodeficiency Virus demonst... more Background Mathematical models of the immune response to the Human Immunodeficiency Virus demonstrate the potential for dynamic schedules of Highly Active Anti-Retroviral Therapy to enhance Cytotoxic Lymphocyte-mediated control of HIV infection. Methods In previous work we have developed a model predictive control (MPC) based method for determining optimal treatment interruption schedules for this purpose. In this paper, we introduce a nonlinear observer for the HIV-immune response system and an integrated output-feedback MPC approach for implementing the treatment interruption scheduling algorithm using the easily available viral load measurements. We use Monte-Carlo approaches to test robustness of the algorithm. Results The nonlinear observer shows robust state tracking while preserving state positivity both for continuous and discrete measurements. The integrated output-feedback MPC algorithm stabilizes the desired steady-state. Monte-Carlo testing shows significant robustness to modeling error, with 90% success rates in stabilizing the desired steady-state with 15% variance from nominal on all model parameters. Conclusions The possibility of enhancing immune responsiveness to HIV through dynamic scheduling of treatment is exciting. Output-feedback Model Predictive Control is uniquely well-suited to solutions of these types of problems. The unique constraints of state positivity and very slow sampling are addressable by using a special-purpose nonlinear state estimator, as described in this paper. This shows the possibility of using output-feedback MPC-based algorithms for this purpose.
UMI, ProQuest ® Dissertations & Theses. The world's most comprehensive collection of dis... more UMI, ProQuest ® Dissertations & Theses. The world's most comprehensive collection of dissertations and theses. Learn more... ProQuest, Exploiting immune response dynamics in HIV therapy. by Zurakowski, Ryan Mark, Ph.D ...
… Control Conference, 2004. …, 2004
… Control Conference (ACC), …, 2010
… Control Conference (ACC), …, 2010
Journal of process …, 2011
American Control Conference, 2006, 2006
… Conference, 2004. 5th …, 2004
Journal of theoretical biology, 2007
… Control Conference, 2009. …, 2009
American Control Conference, 2008, 2008
Decision and Control, 2007 46th …, 2007
Proceedings of the American Control …, 2003
Journal of Theoretical Biology, 2006
Recently developed models of the interaction of the human immune system and the human immunodefic... more Recently developed models of the interaction of the human immune system and the human immunodeficiency virus (HIV) suggest the possibility of using interruptions of highly active anti-retroviral therapy (HAART) to simulate a therapeutic vaccine and induce cytotoxic lymphocyte (CTL) mediated control of HIV infection. We have developed a model predictive control (MPC) based method for determining optimal treatment interruption schedules for this purpose. This method provides a clinically implementable framework for calculating interruption schedules that are robust to errors due to measurement and patient variations. In this paper, we discuss the medical motivation for this work, introduce the MPC-based method, show simulation results, and discuss future work necessary to implement the method.
I. INTRODUCTION The development of resistance to a particular drug regimen necessitates a change ... more I. INTRODUCTION The development of resistance to a particular drug regimen necessitates a change in regimen, and there are, for every ap-plication, only a limited number of drug regimens available. If resistance develops to every available drug regimen, the patient will die. It is ...